As President and CEO of Olink Proteomics the vision and goal is to facilitate and implement Precision Medicine via discovery and development of validated protein targets to identify smaller protein signatures for e.g. stratification and prediction and advance them in to clinical decision making. Jon is an entrepreneur and has spent the last 25 years in various biotech start-up companies, developing and commercializing medical devices and biotech drugs. He studied economy at the Uppsala University and has an MBA from IHM Business school in Stockholm. Jon was part of a small team that started Swedens latest most successful biotech which grew to 800 people around the world, market leader in its segment, went public and eventually sold to Galderma. Prior to joining Olink Proteomics as President and CEO he ran a small orphan drug company developing two drugs into late stage clinical trials through the FDA with novel treatments for hyperoxaluria.
Presentation Title and Company Description
Clinical Dx Showcase: Comprehensive Screening of Validated Protein Biomarkers for Precision Medicine
Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery and development, with rapid, high-throughput immunoassay analysis, exceptional data quality. Disease or biology-focused panels allow simultaneous analysis of 92 to 1,000 biomarkers with 1-15 µl of sample, as fee for service or kits.